

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM837374

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Partial Termination and Release of Security Interest in Trademarks Recorded at Reel 5719, Frame 0623		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
JPMorgan Chase Bank, N.A., as Collateral Agent		08/30/2023	National Association: UNITED STATES
RECEIVING PARTY DATA			
Name:	Alvogen Pharma US, Inc.		
Street Address:	44 Whippany Road, Suite 300		
City:	Morristown		
State/Country:	NEW JERSEY		
Postal Code:	07960		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	3964271	TENORMIN	
Registration Number:	1148645	TENORETIC	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2136207848		
Email:	iprecordations@whitecase.com		
Correspondent Name:	Justine Lu/White & Case LLP		
Address Line 1:	555 South Flower Street, Suite 2700		
Address Line 4:	Los Angeles, CALIFORNIA 90071		
ATTORNEY DOCKET NUMBER:	4434031-0004-S216		
NAME OF SUBMITTER:	Justine Lu		
SIGNATURE:	/Justine Lu/		
DATE SIGNED:	09/06/2023		
Total Attachments: 4			
source=Alvogen - Trademark Release (ABL) (2023 Asset Sale) (Execution Version)#page1.tif			
source=Alvogen - Trademark Release (ABL) (2023 Asset Sale) (Execution Version)#page2.tif			

CH \$65.00 3964271

source=Alvogen - Trademark Release (ABL) (2023 Asset Sale) (Execution Version)#page3.tif

source=Alvogen - Trademark Release (ABL) (2023 Asset Sale) (Execution Version)#page4.tif

**PARTIAL TERMINATION AND RELEASE OF
SECURITY INTEREST IN TRADEMARKS**

This Partial Termination and Release of Security Interest in Trademarks (“Trademark Release”) is made as of August 30, 2023, by **JPMORGAN CHASE BANK, N.A.** (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), in favor of **ALVOGEN PHARMA US, INC.**, a Delaware corporation with an address at 44 Whippany Road, Suite 300, Morristown, New Jersey 07960 (the “Grantor”).

WITNESSETH:

WHEREAS, Alvogen AZ IP Holdings, LLC entered into that certain Trademark Collateral Agreement, dated January 29, 2016 (the “Trademark Security Agreement”), with Collateral Agent, notice of which was recorded on January 29, 2016 at the United States Patent and Trademark Office at Reel 5719, Frame 0623.

Capitalized terms used but not otherwise defined herein have the meanings given to them in the Trademark Security Agreement.

WHEREAS, Alvogen AZ IP Holdings, LLC granted the Collateral Agent, under the terms of the Trademark Security Agreement, a continuing security interest (the “Security Interest”) in favor of the Collateral Agent, in and to all of such Grantor’s Trademark Collateral, including without limitation the Trademarks listed in **Schedule A** hereto.

WHEREAS, Grantor is the current owner of all right, title and interest in the Trademarks listed in **Schedule A** hereto.

WHEREAS, the Collateral Agent has agreed to terminate and release its security interest solely in the Trademark Collateral set forth in **Schedule A** as herein provided.

NOW, THEREFORE, in consideration of the foregoing and intending to be legally bound, the Collateral Agent hereby agrees that:

1. The Collateral Agent, for itself and on behalf of the lenders in association with the Security Interest, hereby releases, terminates and discharges any and all of its interest in the Trademark Collateral of the Grantor set forth on **Schedule A**, and assigns, transfers and conveys to Grantor such interest in the Trademark Collateral.

2. The Collateral Agent authorizes and requests that the United States Patent and Trademark Office and any other applicable government office record this Trademark Release.

3. THIS TRADEMARK RELEASE AND ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS TRADEMARK RELEASE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE


STATE OF NEW YORK (EXCEPT FOR CONFLICTS OF LAW PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION).

[Remainder of this page intentionally left blank; signature page follows]

IN WITNESS WHEREOF, the Collateral Agent has caused this Trademark Release to be executed as of the day and year first written above.

JPMORGAN CHASE BANK, N.A.,
as Collateral Agent

By: _____



Name: Maurice Dattas
Title: Vice President

SCHEDULE A

RELEASED TRADEMARKS

Ser. No.	Reg. No.	Mark	Owner of Record
77957605	3964271	TENORMIN	Alvogen Pharma US, Inc.
73201050	1148645	TENORETIC	Alvogen Pharma US, Inc.